| Similar Articles |
|---|
 |
Chemistry World
April 9, 2015
Emma Stoye |
BMS invests in gene therapy Bristol-Myers Squibb has agreed to invest over $100 million in Netherlands-based biotechnology company uniQure, which specializes in gene therapies for cardiovascular diseases.   |
Chemistry World
January 11, 2016
Phillip Broadwith |
GSK's ViiV to buy HIV drugs from BMS Bristol-Myers Squibb has agreed to sell its entire portfolio of investigational HIV drugs as the company seeks to exit research in virology. |
Chemistry World
September 2007
Derek Lowe |
Column: In the Pipeline Will Phase Zero trials actually help drug development? |
Fast Company
December 2009
Erica Westly |
The Price of Winning FDA Approval Approval for a new drug or medical treatment requires extensive -- and expensive -- human trials for safety and effectiveness. |
The Motley Fool
April 28, 2009
Brian Orelli |
Headline? Bad! Unexpected? No! For a company that only has one drug on the market, stopping a failing phase 3 clinical trial that's designed to expand the market of that drug is usually a major blow. But Onyx Pharmaceuticals was able to shrug it off. |
The Motley Fool
June 29, 2007
Brian Orelli |
The Phase 2 Blues Drug developer Cytokinetics disappoints investors with failed clinical trials. |
The Motley Fool
July 27, 2007
Tom Taulli |
A New Phase for Phase Forward Phase Forward wins a multi-million dollar contract for its clinical trial software; this infusion of cash provides even more resources for pursuing more growth. |
The Motley Fool
April 26, 2007
Tom Taulli |
Phase Forward's False Funk Ignore its stagnant shares -- new deals should continue this company's growth. |
Chemistry World
April 21, 2010
Sarah Houlton |
Fresh hep C hope A new kind of compound to treat hepatitis C is showing promise in early clinical trials. |
Chemistry World
April 2006
Karen Harries-Rees |
Editorial: Drugs Testing on Trial A drugs trial in the UK that went disastrously wrong last month has raised questions about the ethics of using paid volunteers in clinical trials and the usefulness of animal testing. |
Pharmaceutical Executive
June 9, 2014 |
Immunotherapies: The New Hope for Cancer Treatment The Cancer Research Institute is clearing a path to the future of immunotherapeutics. Ben Comer speaks to its CEO and director of scientific affairs, Jill O'Donnell-Tormey |
Chemistry World
September 2009 |
Column: In the pipeline What's the most difficult therapeutic area for drug discovery? They're certainly not all created equal - or if they were, they have definitely diverged since then. The question can be narrowed down quite a bit. |
Chemistry World
October 15, 2013
Dinsa Sachan |
Supreme court ruling brings clinical trials to a halt in India The fate of 162 global clinical trials hangs in the balance, as the top Indian court has asked the government to provide more details on their approval process before they can proceed. |
Chemistry World
August 27, 2014
Phillip Broadwith |
Clinical collaborations drive cancer immunotherapy A joint clinical trial agreement between Merck & Co and Pfizer is the latest in a rather tangled web of tie-ups between companies with cancer drugs that harness patients' immune systems. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Cancer: On Target Once More Over the past year or two, a handful of Phase III failures, including megablockbusters like Avastin and Sutent in trials for all kinds of common tumors, indicate that targeted therapy is generally a blunt instrument. |
Pharmaceutical Executive
October 1, 2006
Clinton & Koroneos |
Learn & Confirm At Wyeth, a sweeping set of initiatives is transforming the R&D operation - and spotlighting a possible future for drug development. |
Chemistry World
January 11, 2012
Andrew Turley |
BMS spends $2.5 billion on antiviral firm The move will stock Bristol-Myers Squibb's pipeline with antivirals, most notably INX-189, a nucleotide polymerase inhibitor which is in Phase II trials for treating hepatitis C virus infection. |
Chemistry World
January 25, 2013
Rajesh Parishwad |
Indian supreme court's anger over unregulated clinical trials The fledgling clinical trials industry in India has been hit by recent revelations of a lack of regulation. Now, the country's supreme court has criticized the body that oversees clinical trials for its inaction in the face of these unethical practices. |
Investment Advisor
December 2005
Greg B. Scott |
Buying The Future Prudent investing in biotechnology can offer great returns for clients. It's also the wave of the future. Armed with a basic understanding of the dynamics of the industry and the valuation inflection points, intelligent investors can make significant returns. |
The Motley Fool
August 2, 2004
Charly Travers |
What's a Drug Worth? The value of small biotech companies is in their investigational drug programs. |
Chemistry World
November 12, 2013
Dinsa Sachan |
Rough patch for India's clinical trial industry The Indian clinical trial industry is beset by uncertainty. Campaigners have petitioned the courts claiming that drug companies are exploiting poor people and this has led to more than 100 trials being put on hold. |
Chemistry World
March 14, 2014
Phillip Broadwith |
Bristol-Myers Squibb to close Irish plant BMS tied the closure to 'changing market demand' for its products, along with efforts to optimize its manufacturing network. |
Chemistry World
June 12, 2014
Andy Extance |
Pharma vies to unleash immune system power on cancer Drug firms are investing heavily in clinical trials and collaborations as they seek to capitalize on the potential of cancer therapies that enlist or enhance our immune systems' ability to fight tumors. |
Pharmaceutical Executive
February 1, 2007
John Smith |
Public Relations: Beef Up Clinical Trial Numbers Web-based public relations can make the difference in clinical-trial recruitment. |
Chemistry World
April 4, 2013
Phillip Broadwith |
Amylin headquarters to close with further job losses Bristol-Myers Squibb has confirmed that it will be closing the site in San Diego, US, which was formerly the corporate headquarters of biotech firm Amylin. |
Salon.com
June 1, 2000
Tabitha M. Powledge |
Gene therapy R.I.P.? When the country's biggest gene therapy institute was ordered to stop testing on humans last week, the action marked the end of an era fraught with dubious claims to success and a mess of unreported adverse effects. |
Pharmaceutical Executive
November 1, 2014
Josh Baxt |
2015 Pipeline Report: Burning Bright The science of drug discovery is back on script and the stars are cued up for a new generation of breakthrough therapies. |
Chemistry World
October 19, 2015
Philippa Matthews |
BMS agrees $1.7bn immuno-oncology collaboration Bristol-Myers Squibb has entered into a worldwide license and collaboration with Five Prime Therapeutics to develop and commercialize Five Prime's colony stimulating factor 1 receptor (CSF1R) antibodies. |
AskMen.com
Richard Stevens |
Participating In Clinical Trials Check out what participating in clinical trials involves and how you can join a study. You may even make some cash in the process. |
AskMen.com
Joshua Levine |
Selling Your Body To Science Have you ever thought about the number of voluntary patients who basically sell their bodies to clinical trials in the name of science? Well, the number is staggering and it can reach well into the thousands. The main reason being the large paycheck that comes with the job. |
Pharmaceutical Executive
May 1, 2009 |
The Shakeout When it comes to licensing in this market, there are winners and losers. Learn the new rules of the game. |
The Motley Fool
June 21, 2004
Brian Gorman |
Clinical Trials Controversy The American Medical Association wants more transparency in clinical trials, a proposal that may leave drug companies and investors with mixed feelings. |
Pharmaceutical Executive
August 1, 2005
Joanna Breitstein |
Weathering the Storm Out from financial scandal, CEO Peter Dolan is steering Bristol-Myers Squibb's most productive pipeline yet. |
Information Today
July 2, 2013 |
Thomson Reuters Offers Clinical Trial Intelligence Solutions These solutions improve clinical trials, speed up product development and release, and help professionals strengthen portfolios and R&D strategy. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
The Next Wave: Pharm Exec's 2011 Pipeline Report 42 of the best new drugs in development or parked at the FDA |
Chemistry World
October 7, 2015
Phillip Broadwith |
Bristol-Myers-Squibb fined for alleged Chinese bribes The US Securities and Exchange Commission has fined New York based pharmaceutical company Bristol-Myers Squibb over $14 million over alleged bribes made to Chinese state owned hospitals. |
Chemistry World
December 20, 2013
Patrick Walter |
AstraZeneca shells out $4.1bn for diabetes business AstraZeneca has agreed to pay Bristol-Myers Squibb up to $4.1 billion for its share of the pharma giants' diabetes joint venture. |
The Motley Fool
February 1, 2008
Brian Lawler |
Credit Crisis Bites Big Pharma Bristol-Myers Squibb takes a $275 million writedown in its investment portfolio for the quarter. |
Bio-IT World
May 9, 2003
Mark D. Uehling |
Data Rapture? Electronic capture of data: Some say it unclogs the medieval clinical trials process. Others remain skeptical of software and put their trust in paper. |
Bio-IT World
July 2005
Kevin Davies |
Medicine Gets Personal Touch More genomics-based drugs are moving into development with others, such as new cancer drugs showcasing on the clinical pharmacogenics scene as outlined in the Advances in Genomic Medicine program of a recent world conference. |
Bio-IT World
August 13, 2002
Mark D. Uehling |
Clinical Trial Data Management: Tortured by Paper Reams of paper stuffed into boxes and shipped to the FDA by the truckload is hardly the best approach to drug approval. But what's the right way? |
Pharmaceutical Executive
September 1, 2008
Melanie North |
Publish or Perish FDAAA means that companies need to register clinical trials; and not only for publication planning. |
Pharmaceutical Executive
December 1, 2008
Walter Armstrong |
The New Deals Everything you wanted to know about the year's most important deals, and what to watch for in the future. |
Chemistry World
June 5, 2015
Rebecca Trager |
BMS sues executive for joining rival company Bristol-Myers Squibb has filed a lawsuit against a former executive who quit suddenly last month to work for a direct competitor, AstraZeneca. |
